Matinas BioPharma Holdings, Inc.
MTNB · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1,096 | $3,188 | $33 |
| % Growth | -100% | -65.6% | 9,560.6% | – |
| Cost of Goods Sold | $0 | $0 | $16,678 | $14,583 |
| Gross Profit | $0 | $1,096 | -$13,490 | -$14,550 |
| % Margin | – | 100% | -423.1% | -44,090.9% |
| R&D Expenses | $11,433 | $14,489 | $16,678 | $14,583 |
| G&A Expenses | $8,729 | $10,373 | $11,100 | $10,185 |
| SG&A Expenses | $8,729 | $10,373 | $11,100 | $10,185 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4,431 | $0 | -$16,678 | -$14,583 |
| Operating Expenses | $24,593 | $24,862 | $11,100 | $10,185 |
| Operating Income | -$24,593 | -$23,766 | -$24,590 | -$24,735 |
| % Margin | – | -2,168.4% | -771.3% | -74,954.5% |
| Other Income/Exp. Net | $262 | $824 | $3,593 | $1,452 |
| Pre-Tax Income | -$24,331 | -$22,942 | -$20,997 | -$23,283 |
| Tax Expense | -$80 | $0 | $0 | $0 |
| Net Income | -$24,251 | -$22,942 | -$20,997 | -$23,283 |
| % Margin | – | -2,093.2% | -658.6% | -70,554.5% |
| EPS | -4.98 | -5.28 | -3 | -5.04 |
| % Growth | 5.7% | -76% | 40.5% | – |
| EPS Diluted | -4.98 | -5.28 | -3 | -5.04 |
| Weighted Avg Shares Out | 4,866 | 4,345 | 4,336 | 4,204 |
| Weighted Avg Shares Out Dil | 4,866 | 4,345 | 4,336 | 4,204 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $972 | $941 | $356 | $280 |
| EBITDA | -$19,190 | -$22,825 | -$24,234 | -$24,455 |
| % Margin | – | -2,082.6% | -760.2% | -74,106.1% |